Western blot (WB) and immunoprecipitation (IP) analyses were performed as described previously [22]. The following antibodies were used in this study: Primary antibodies included phospho-AKT at S473 (#4060), phospho-AKT at T308 (#13038), phospho-Foxo3α at Thr32 9 (#9464), phospho-AMPKα1 at Thr172 (#2535), phospho-p70S6K at Thr389 (#9206), phospho-SIN1 at Thr86 (#14716S), phospho-NDRG1 at Thr346 (#5482), phospho-p53 at Ser6 (#9285), Ser9 (#9288), Ser15 (#9284), Ser20 (#9287), and Ser37 (#9289), phospho-pRb at Ser807/811 (#9308), mTOR (#2972), Raptor (#2280), Rictor (#2140), TSC2 (#6935), 4EBP1 (#9452), and phospho-4EBP1 at Thr37/46 (#2855) (Cell Signaling Technology, Danvers, MA, USA); PTEN (#SC-7974), MDM2 (#SC-965), phospho-PKCα at Ser657 (#SC-12356), and p21 (#SC-397) (SantaCruz, Dallas, TX, USA); p53 (#NCL-L-p53-DO7) (DO7, Leica, Milton Keynes, UK); Actin (#G043) (Applied Biological Materials Inc.); Flag (#A8592), and Catalase (#C-0979) (Sigma); Myc (#OP10) (Calbiochem, CA, USA).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.